Page last updated: 2024-11-13

difenacoum

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diphenacoum: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54676884
CHEBI ID80743
SCHEMBL ID122475
SCHEMBL ID122474
MeSH IDM0060268

Synonyms (47)

Synonym
AC-12415
hsdb 6609
3-(3-p-diphenyl-1,2,3,4-tetrahydronaphth-1-yl) -4-hydroxycoumarin
ratak
wba 8107
difenakum [czech]
neosorexa
einecs 259-978-4
difenacoum [bsi:iso]
diphenacoum
3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin
2h-1-benzopyran-2-one, 3-(3-(1,1'-biphenyl)-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy-
difenacoum
neosorexa pp580
3-(3-(1,1'-biphenyl)-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy-2h-1-benzopyran-2-one
coumarin, 3-(3-(4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxy-
56073-07-5
pp, rat
bdbm85791
AKOS015960905
sba3k9u26b ,
difenakum
unii-sba3k9u26b
SCHEMBL122475
SCHEMBL122474
3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4- hydroxycoumarin
difenacoum [mi]
3-(3-p-diphenyl-1,2,3,4-tetrahydronaphth-1-yl) -4- hydroxycoumarin
difenacoum [iso]
diphenacoum [hsdb]
2h-1-benzopyran-2-one, 3-(3-(1,1'-biphenyl)-4-yl-1,2,3,4- tetrahydro-1-naphthalenyl)-4-hydroxy-
3-(3-(1,1'-biphenyl)-4-yl-1,2,3,4-tetrahydro-1- naphthalenyl)-4-hydroxy-2h-1-benzopyran-2-one
coumarin, 3-(3-(4-biphenylyl)-1,2,3,4-tetrahydro-1- naphthyl)-4-hydroxy-
CHEBI:80743
DTXSID2058128
pp 580
FVQITOLOYMWVFU-UHFFFAOYSA-N
3-(3-[1,1'-biphenyl]-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy-2h-chromen-2-one #
2h-1-benzopyran-2-one, 3-(3-[1,1'-biphenyl]-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy-
3-(3-(4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin
neosorex
difenacoum, pestanal(r), analytical standard
difenacoum 100 microg/ml in methanol
difenacoum 10 microg/ml in methanol
2h-1-benzopyran-2-one, 3-(3-[1,1'-biphenyl]-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy-; difenacoum; diphenacoum; neosorexa; ratak
Q424775
4-hydroxy-3-[3-(4-phenylphenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]chromen-2-one

Research Excerpts

Overview

Difenacoum is a long-acting superwarfarin-type anticoagulant. exerts its effect through inhibiting vitamin K 2,3-epoxide reductase.

ExcerptReferenceRelevance
"Difenacoum is a long-acting superwarfarin-type anticoagulant that exerts its effect through inhibiting vitamin K 2,3-epoxide reductase. "( Superwarfarin poisoning and its management.
Card, DJ; Deuchande, K; Francis, S; Harrington, DJ, 2014
)
1.85

Treatment

ExcerptReferenceRelevance
"Six difenacoum treatments failed in 14--42 days of baiting."( Field trials of second-generation anticoagulants against difenacoum-resistant Norway rat populations.
Greaves, JH; Quy, R; Shepherd, DS, 1982
)
0.99

Bioavailability

ExcerptReferenceRelevance
"The differences in chemical structure between DFM on the one hand and BFM, FLO and DFTL on the other could explain the differences in bioavailability between these two groups of molecules."( Mass spectrometry characterization of anticoagulant rodenticides and hydroxyl metabolites.
Benoit, E; Berlioz-Barbier, A; Fourel, I, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (57)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (35.09)18.7374
1990's8 (14.04)18.2507
2000's6 (10.53)29.6817
2010's18 (31.58)24.3611
2020's5 (8.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.43 (24.57)
Research Supply Index4.16 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index87.44 (26.88)
Search Engine Supply Index3.99 (0.95)

This Compound (33.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies13 (20.63%)4.05%
Observational0 (0.00%)0.25%
Other50 (79.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]